Latest Insider Transactions at G1 Therapeutics, Inc. (GTHX)
This section provides a real-time view of insider transactions for G1 Therapeutics, Inc. (GTHX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of G1 Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of G1 Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 18
2024
|
Glenn P Muir |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
185,358
-100.0%
|
-
|
|
Sep 18
2024
|
Glenn P Muir |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-9.74%
|
-
|
|
Sep 18
2024
|
Andrew Perry Chief Commercial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,232
-100.0%
|
-
|
|
Sep 18
2024
|
Andrew Perry Chief Commercial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
114,482
-88.94%
|
-
|
|
Sep 18
2024
|
Andrew Perry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,100
+11.12%
|
-
|
|
Sep 18
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
21,150
-100.0%
|
-
|
|
Sep 18
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
124,762
-85.51%
|
-
|
|
Sep 18
2024
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,900
+10.93%
|
-
|
|
Sep 18
2024
|
Mark Avagliano Chief Business Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
26,035
-100.0%
|
-
|
|
Sep 18
2024
|
Mark Avagliano Chief Business Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
236,610
-90.09%
|
-
|
|
Sep 18
2024
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,600
+7.27%
|
-
|
|
Sep 18
2024
|
Norman Sharpless |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-100.0%
|
-
|
|
Sep 18
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
87,450
-100.0%
|
-
|
|
Sep 18
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
89,762
-50.65%
|
-
|
|
Sep 18
2024
|
Rajesh Malik Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,900
+9.17%
|
-
|
|
Sep 18
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
196,287
-100.0%
|
-
|
|
Sep 18
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
534,787
-73.15%
|
-
|
|
Sep 18
2024
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
181,400
+19.88%
|
-
|
|
Sep 18
2024
|
John V. Umstead Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
19,331
-100.0%
|
-
|
|
Sep 18
2024
|
John V. Umstead Chief Financial Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
168,387
-89.7%
|
-
|
|
Sep 18
2024
|
Garry A Nicholson |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,389
-100.0%
|
-
|
|
Sep 18
2024
|
Garry A Nicholson |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-58.16%
|
-
|
|
Sep 18
2024
|
Jacks Lee |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,000
-100.0%
|
-
|
|
Sep 18
2024
|
Jacks Lee |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,000
-50.0%
|
-
|
|
Sep 18
2024
|
Cynthia Schwalm |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
15,889
-100.0%
|
-
|
|
Sep 18
2024
|
Cynthia Schwalm |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-55.73%
|
-
|
|
Sep 18
2024
|
Monica R. Thomas Chief Legal & People Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
6,674
-100.0%
|
-
|
|
Sep 18
2024
|
Monica R. Thomas Chief Legal & People Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
138,151
-95.39%
|
-
|
|
Sep 18
2024
|
Alicia Secor |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,000
-100.0%
|
-
|
|
Sep 18
2024
|
Alicia Secor |
SELL
Sale (or disposition) back to the issuer
|
Direct |
20,000
-66.67%
|
-
|
|
Jul 05
2024
|
Andrew Perry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,337
-1.17%
|
$2,674
$2.51 P/Share
|
|
Jul 05
2024
|
John V. Umstead Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
527
-0.28%
|
$1,054
$2.51 P/Share
|
|
Jul 05
2024
|
Mark Avagliano Chief Business Officer |
SELL
Open market or private sale
|
Direct |
2,638
-1.08%
|
$5,276
$2.51 P/Share
|
|
Jul 05
2024
|
Rajesh Malik Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,475
-1.53%
|
$4,950
$2.51 P/Share
|
|
Jul 05
2024
|
Terry L Murdock Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
2,475
-1.9%
|
$4,950
$2.51 P/Share
|
|
Jul 05
2024
|
John E. (Jack) Bailey Jr. President and CEO |
SELL
Open market or private sale
|
Direct |
7,662
-1.37%
|
$15,324
$2.51 P/Share
|
|
Jul 01
2024
|
Terry L Murdock Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+21.15%
|
-
|
|
Jul 01
2024
|
Andrew Perry Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+23.5%
|
-
|
|
Jul 01
2024
|
Mark Avagliano Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+12.51%
|
-
|
|
Jul 01
2024
|
Monica R. Thomas Chief Legal & People Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+19.46%
|
-
|
|
Jul 01
2024
|
John E. (Jack) Bailey Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
105,000
+15.85%
|
-
|
|
Jul 01
2024
|
John V. Umstead Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+15.68%
|
-
|
|
Jun 13
2024
|
Jacks Lee |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+33.33%
|
-
|
|
Jun 13
2024
|
Glenn P Muir |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+4.64%
|
-
|
|
Jun 13
2024
|
Alicia Secor |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+25.0%
|
-
|
|
Jun 13
2024
|
Norman Sharpless |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+33.33%
|
-
|
|
Jun 13
2024
|
Garry A Nicholson |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+22.53%
|
-
|
|
Jun 13
2024
|
Cynthia Schwalm |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+21.79%
|
-
|
|
May 23
2024
|
Monica R. Thomas Chief Legal & People Officer |
SELL
Open market or private sale
|
Direct |
5,826
-5.04%
|
$23,304
$4.27 P/Share
|
|
May 13
2024
|
Andrew Perry Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
8,151
-9.36%
|
$32,604
$4.79 P/Share
|